Download PDF

International Journal of Environmental Research and Public Health

Publication date: 2017-09-01
Volume: 14 11
Publisher: Molecular Diversity Preservation International

Author:

Liu, X
Blaschke, T ; Thomas, B ; De Geest, Sabina ; Jiang, S ; Gao, Y ; Li, X ; Buono, ew ; Buchanan, S ; Zhang, Z ; Huan, S

Keywords:

Science & Technology, Life Sciences & Biomedicine, Environmental Sciences, Public, Environmental & Occupational Health, Environmental Sciences & Ecology, adherence, tuberculosis, management, monitoring technology, usability, DIRECTLY OBSERVED THERAPY, CONSENSUS, TAXONOMY, DEVICES, Antitubercular Agents, Medication Adherence, Reminder Systems, Tuberculosis, Tuberculosis, Multidrug-Resistant, Toxicology

Abstract:

Poor initiation and implementation and premature discontinuation of anti-tuberculous therapy, all forms of nonadherence, are major reasons for treatment failure, the development of drug-resistant tuberculosis, and transmission to other non-infected individuals. Directly Observed Therapy (DOT) has been the worldwide standard, but implementation of DOT is burdensome for providers and patients, especially in resource-limited settings, where most of the burden of active TB is located. Among the alternatives to DOT is electronic monitoring (EM) of drug dosing histories. Here we report a usability study of a newly-designed, modular electronic monitor product, called the MERM (Medication Event and Reminder Monitor), that is compatible with TB medication formats and supply chains in resource-limited settings. This study, done in a rural setting in China, showed that the use of the MERM for EM of TB medications was associated with a high degree of user performance, acceptability, and satisfaction among both TB patients and medical staff. Based on these data, EM is becoming the standard of care for drug-susceptible TB patients in China and scaled implementations in several other countries with high TB burden have begun. In addition, the MERM is being used in MDR-TB patients and in clinical trials involving patients with TB/HIV and latent TB.